MedPath

Hua Medicine's Dorzagliatin Shows Promise in Restoring β-Cell Glucose Sensitivity in Asian Populations

• Hua Medicine announced positive results from its SENSITIZE study, demonstrating dorzagliatin's ability to improve β-cell glucose sensitivity. • The SENSITIZE 2 study showed a single dose of dorzagliatin restores glucokinase enzyme activity in individuals with impaired glucose tolerance. • Prior SENSITIZE 1 study indicated dorzagliatin enhances insulin secretion in GCK-MODY patients and newly diagnosed type 2 diabetes patients. • Hua Medicine plans further investigations into dorzagliatin's effects on glucose sensitivity and incretin response for personalized diabetes treatment.

Hua Medicine announced the successful completion of its SENSITIZE study, revealing insights into how dorzagliatin enhances β-cell glucose sensitivity. The announcement was made at the 9th China BioMed Innovation and Investment Conference (CBIIC). The study, led by Professor Juliana Chan at The Chinese University of Hong Kong, marks the first clinical evaluation in Asian populations assessing the impact of glucokinase activators (GKAs) on β-cell function using hyperglycemic clamp technology.
The SENSITIZE study aimed to elucidate the role of impaired glucokinase (GK) function in various glucose dysregulation types, offering new evidence on the pathophysiology of Asian Type 2 diabetes and GK's central role in glucose regulation. The SENSITIZE 2 study results, presented at CBIIC, showed that a single dose of dorzagliatin effectively restores GK enzyme activity. This restoration significantly improved second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) during a hyperglycemic clamp study.

Prior SENSITIZE 1 Study Findings

Previously reported at the 2022 ADA annual meeting, the SENSITIZE 1 study demonstrated that dorzagliatin directly restores the activity of GK mutants. This led to significant improvements in second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2). The study also showed enhanced basal insulin secretion in newly diagnosed type 2 diabetes patients.

Future Research Directions

Hua Medicine intends to continue investigating the effects of repeated dorzagliatin doses on β-cell glucose sensitivity and incretin response in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes. The goal is to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.

About Dorzagliatin

Dorzagliatin, marketed as HuaTangNing in China, is an innovative oral drug that targets glucokinase, a key glucose sensor. It is designed to restore glucose sensitivity in T2D patients and stabilize blood glucose levels. Approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022, dorzagliatin can be used as a monotherapy or in combination with metformin for adult T2D patients, including those with chronic kidney disease (CKD) without requiring dose adjustment.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Mifepristone Demonstrates Significant HbA1c Reduction in CATALYST Trial for Hypercortisolism and Difficult-to-Control Type 2 Diabetes

Mifepristone (Korlym) achieved a statistically significant 1.32% placebo-adjusted reduction in HbA1c in patients with hypercortisolism and difficult-to-control type 2 diabetes.
The CATALYST trial revealed that approximately 23.8% of patients with difficult-to-control type 2 diabetes also have hypercortisolism.

Hua Medicine's Second-Generation GKA Candidate HM-002-1005 Shows Promise in Phase I Trial

Hua Medicine's HM-002-1005, a second-generation glucokinase activator (GKA), has successfully completed a Phase I clinical trial in the U.S..
The trial demonstrated that HM-002-1005 is rapidly converted to dorzagliatin (HMS5552) in the body, with pharmacokinetic properties supporting once-daily oral administration.

GSK's Linerixibat Shows Promise for Cholestatic Pruritus in Phase III Trial

GSK's linerixibat met the primary endpoint in the Phase III GLISTEN study, demonstrating a statistically significant improvement in itch score for PBC patients.
The GLISTEN study evaluated linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), over a 24-week period compared to placebo.

GSK's Linerixibat Shows Positive Phase III Results for Cholestatic Pruritus in PBC

GSK's linerixibat met the primary endpoint in the GLISTEN phase III trial, demonstrating a statistically significant reduction in itch for PBC patients.
The trial included PBC patients with moderate to severe itch, already on stable doses of guideline-suggested therapies, treatment-naïve, or previously treated.

GSK's Linerixibat Shows Promise in Reducing Itch for PBC Patients in Phase 3 Trial

GSK's linerixibat met its primary endpoint in a Phase 3 trial, demonstrating a significant reduction in itch for patients with primary biliary cholangitis (PBC).
The positive results pave the way for regulatory filings, potentially offering a new treatment option for PBC-related pruritus.

Soligenix Initiates Phase 2 Trial of Dusquetide (SGX945) for Behçet's Disease

Soligenix has commenced patient enrollment in a Phase 2 clinical trial evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease.
The open-label study will enroll approximately 25 patients with mild to moderate Behçet's Disease, assessing lesion clearance and quality of life.

Diamyd Demonstrates Robust Treatment Effects in Type 1 Diabetes Trials

Meta-analysis of Diamyd trials reveals significant C-peptide preservation in DR3-DQ2 positive patients with Type 1 Diabetes, suggesting potential for precision medicine.
Combined analysis of 208 patients showed a 48.3% improvement in C-peptide preservation (p < 0.0001) and a reduction in HbA1c of -4.8 mmol/mol (p = 0.0044).

Collagen Peptides Show Promise in Reducing Post-Meal Blood Glucose Spikes

A new study reveals that specific collagen peptides can significantly reduce post-meal blood glucose spikes in healthy individuals and those with prediabetes.
Participants consuming 5 or 10 grams of Nextida GC experienced an average 42% reduction in blood glucose spike 30 minutes after a meal.

Gan & Lee's Once-Weekly Insulin GZR4 Shows Promising Phase I Results in Type 2 Diabetes

Gan & Lee's GZR4, a novel once-weekly insulin analog, demonstrated favorable safety and tolerability in healthy subjects in a Phase Ia clinical study.
Phase Ia study results suggest GZR4 maintains a stable glucose-lowering effect for up to one week with a single administration.

GSK's Depemokimab Shows Promise in Reducing Severe Asthma Exacerbations

Depemokimab significantly reduced severe asthma attacks by 54% compared to placebo in Phase 3 trials, offering a potential new treatment option.
The ultra-long-acting biologic showed a 72% reduction in exacerbations requiring hospitalization or emergency department visits, highlighting its clinical impact.

Reference News

[1]
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC - ACN Newswire
en.acnnewswire.com · Nov 30, 2024

Hua Medicine announced SENSITIZE study results at CBIIC, showing dorzagliatin improves β-cell glucose sensitivity in IGT...

[2]
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
acnnewswire.com · Nov 30, 2024

Hua Medicine announced successful completion of SENSITIZE study at CBIIC, showing dorzagliatin improves β-cell glucose s...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy